Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FB101 Intervention in Asymptomatic Healthy Volunteers Who Have Undergone Vaginal Microbiome Screening - a Randomised, Double-blind, Placebo-controlled Study

X
Trial Profile

FB101 Intervention in Asymptomatic Healthy Volunteers Who Have Undergone Vaginal Microbiome Screening - a Randomised, Double-blind, Placebo-controlled Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FB 101 (Primary)
  • Indications Dysbiosis; Female infertility
  • Focus Therapeutic Use
  • Acronyms DYSCOVER-1
  • Sponsors Freya Biosciences
  • Most Recent Events

    • 27 Jun 2023 According to Freya Biosciences Media Release, initial results will be shared by Johan van Hylckama Vlieg, Chief Scientific Officer of Freya Biosciences at the Microbiome Movement Summit in Boston later this month.
    • 27 Jun 2023 Results published in the Freya Biosciences Media Release
    • 01 May 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top